Stocktoria
Lucid Diagnostics Inc. LUCD
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-10-14
Lucid Diagnostics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 100.0% | 100.0% | — |
| Operating margin | -1054.8% | -1059.6% | -1996.8% | -14920.7% | -5483.8% | — |
| Net margin | -1232.7% | -1047.6% | -2169.1% | -14899.5% | -5615.6% | — |
| FCF margin | -992.0% | -1022.5% | — | -8722.8% | -3706.0% | — |
| Return on assets | -143.4% | -148.2% | -193.1% | -172.8% | -47.6% | -377.2% |
| Return on equity | -530.4% | -844.5% | 2278.9% | -243.7% | -51.3% | 61.3% |
| Debt / equity | — | — | — | — | — | -0.98× |
| Current ratio | 1.31 | 1.07 | 0.75 | 2.89 | 13.45 | — |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.